Gefitinib: A Breakthrough in Targeted Cancer Therapy
Gefitinib is an epidermal growth factor receptor (EGFR) inhibitor that belongs to the class of tyrosine kinase inhibitors (TKIs). It specifically targets cancer cells that exhibit mutations in the EGFR gene,
